Despite high borrowing costs and extended hold times in 2024, dealmaking roared ahead for healthcare private equity with a ...

Despite the pause, the company clarified that the suspension does not impact commercial activity outside the US.

Leuven, Belgium-based Capricorn Partners, announced the first close of its Capricorn Health-tech Fund II at €51M.

This latest investment, which brings OXcan’s total funding to date to $16.7 million, will be used to develop and globally ...

Bernstein raised the firm’s price target on Stryker (SYK) to $425 from $410 and keeps an Outperform rating on the shares as part of a broader ...

Bernstein raised the firm’s price target on Insulet (PODD) to $315 from $305 and keeps an Outperform rating on the shares as part of a broader ...

Bernstein raised the firm’s price target on DexCom (DXCM) to $89 from $86 and keeps an Outperform rating on the shares as part of a broader ...

As a wave of volatility has been re-introduced to the system, investors are flocking toward blue-chip companies for stability ...

FlowBeams, creator of the BoldJet needle-free injection showcased itsbreakthrough medtech technology at CES 2025.The company’s innovative needle-free injection ...

Boston Scientific stock popped Wednesday after the medtech giant agreed to full acquire Bolt Medical for up to $900 million.

The temporary halt to investigate reported neurovascular events comes two months after Johnson & Johnson won FDA approval for ...

The temporary pause will allow the company to investigate four neurovascular events seen in an external validation study.